HOME >> MEDICINE >> NEWS
Results of NUVANCE (IL-4 receptor) in Phase I/II study in asthma patients featured at AAAAI Late-Breaker Abstract and Asthma Therapy Sessions

SAN DIEGO - The results of a Phase I/II study of NUVANCE™ (IL-4 receptor) in adult patients with moderate asthma will be featured at the Late-Breaker Abstract Session at the American Academy of Allergy, Asthma and Immunology's (AAAAI) 56th Annual Meeting (March 3-8 in San Diego, California).

WHEN: Saturday, March 4, 2000, 3:00 pm

WHERE: Late Breaker: New Therapies Mini-symposium, Room 8, Upper Level of the San Diego Convention Center.

WHO: Dr. Jonathan Corren, MD, Medical Director, Allergy Research Foundation, and lead investigator will present the results of Phase I/II study of NUVANCE™ in adult patients with moderate asthma. Dr. Corren is affiliated with the University of California, Los Angeles.

A presentation entitled, "Cytokines and Cytokine Therapy for Allergic Diseases: Which One is the Most Critical? Il-4 and IL-4 Receptor Antagonists in Allergic Disease," will also be featured at the AAAAI Annual Meeting.

WHEN: Monday, March 6, 2000, 8:45 am - 10:45 am

WHERE: Asthma Therapy Symposium, Marina Ballroom G, Level 3, South Tower, Marriott.

WHO: Dr. Jan Agosti, Medical Director, Immunex Corp., will present scientific evidence and clinical data demonstrating the potential of IL-4 inhibition to improve lung function and control the symptoms of people with asthma.

Interleukin-4 (IL-4) is a naturally occurring cytokine, or immune system protein, that has been commonly associated with the development of asthma and allergies. It binds to specific IL-4 receptors (IL-4R) on the surface of cells in the body or to naturally occurring soluble receptors that circulate throughout the body. Increased levels of IL-4 appear to be related to increased severity of asthma that results in difficulty in breathing. Immunex scientists used recombinant DNA technology to produce a soluble IL-4 receptor, a molecule the company names NUVANCE. When IL-4 binds with NUVANCE instead of cell-surface IL-4R, the effects of IL-4 may be block
'"/>

Contact: Tim Warner
warnert@immunex.com
206-470-4193
Immunex Corporation
1-Mar-2000


Page: 1 2

Related medicine news :

1. Heart transplant survival: Results may be key to rejection prevention, detection, treatment
2. Docetaxel versus paclitaxel in breast cancer Results of worlds first head to head trial
3. Results from first clinical trial using GVG to treat addiction
4. Results of first chronic treatment study with oral EXANTA(TM) (ximelagatran)
5. Media Advisory-- Results of California autism epidemiology study to be unveiled
6. Results of Yale study confirm aspirin helpful in preventing a first heart attack
7. Yale study shows way to re-stimulate brain cell growth: Results could boost understanding of Alzheimers, other brain disorders
8. Results of NUVANCE phase I/II asthma trial presented
9. ILEX Oncology & LeukoSite report results from pivotal Phase II CAMPATH (R) trial; Results suggest new hope for refractory chronic lymphocytic leukemia
10. UI Study Yields Encouraging Results For New Breast Cancer Treatment
11. Ph.D. Degree Research Results In Patent For Low-Cost Pharmaceutical Filters Made From Seafood Waste

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:9/3/2020)... ... September 03, 2020 , ... International Dark-Sky ... WALI wireless parking lot controller. This advanced LED wireless dimming controller, along with ... and protecting the night sky against light pollution. Leo Smith, the Northeast Regional ...
(Date:9/1/2020)... ... September 01, 2020 , ... Feeding Matters , ... children with Pediatric Feeding Disorder (PFD), is pleased to announce that the U.S. Centers ... diagnostic code (R code) in the next edition of the U.S. International Classification ...
(Date:8/31/2020)... NEW YORK (PRWEB) , ... August 31, 2020 ... ... the nation’s largest non-profit organization devoted exclusively to funding innovative lymphoma research and ... and patient services – today announced the 10th Anniversary of Blood Cancer Awareness ...
(Date:8/31/2020)... ... August 31, 2020 , ... Genesis ... chiropractors, announced today the launch of its integrated, HIPAA compliant, telehealth solution, available ... virtual practice in under 90 seconds. , According to the U.S. Department ...
(Date:8/31/2020)... , ... August 31, 2020 , ... A Cure for Covid-19 “PTS” with Mediation & ... the planet are in a state of panic, experiencing deep anxiety, immense stress, and right ... a solution is timely when most people on the planet are experiencing a great degree ...
Breaking Medicine News(10 mins):
(Date:9/3/2020)... ... ... Using Analysis of Variance — A Practical Approach:, Perform Statistical Analysis Without ... https://www.fdanews.com/anova , How much would it help one’s Quality Management System if ... 90 minutes, one can master a powerful statistical technique in that time — Analysis ...
(Date:9/2/2020)... ... September 02, 2020 , ... ... Penetration Technology, LLC, (APT) a Texas- and Indiana-based company ( http://www.aptt3x.com ) ... Counter (OTC) products, was today provided results of an independent laboratory evaluation ...
(Date:9/1/2020)... ... September 01, 2020 , ... Mara C. Weinstein Velez, M.D., ... the University of Rochester Medical Center, in Upstate New York. She completed a ... clinical faculty from the Harvard and Yale Departments of Dermatology and is one ...
Breaking Medicine Technology:
Cached News: